Propagation and quantification of obligate intracellular pathogens are both labor-intensive and costly undertakings. These characteristics, coupled with C. burnetii's highly infectious nature and select agent designation, complicate the most basic research endeavors. However, because highly purified and enumerated C. burnetii is essential to the proposed research, a dedicated core facility with BSL 3 containment, highly trained technical personnel, and an archival system is proposed. Thus, the purpose of the Core B is to make available to each of the 4 Montana Coxiella projects expertise in the cultivation, purification, enumeration, and archiving of phase 1 and 2 Coxiella burnetii. The core will be located at Montana State University, the location of the BSL-3 facilities, and will be directed by Allen Harmsen of Montana State University. Collaborations among projects. Core B will provide services to each of the 4 research projects of the Montana Coxiella group as well as any other RMRCE investigator needing their service. These services will include making standardized inocula of phase 1 and 2 Coxiella burnetii as well as the Crazy strain of Coxiella, as well as the services of standardized Coxiella enumeration and archival of Coxiella organisms. In addition, the two part- time technicians are trained specifically in doing lung infections in mice in the BSL-3. When not engaged in their other activities, the Core B technicians will be available to assist the 4 Montana Coxiella projects on days they sacrifice mice since these time points are labor intensive. Our BSL3 SOP requires a "buddy system" and individuals are not allowed to work alone in the facility. It is much more economical to have two part time floating positions rather than for each of the individual research projects to fund full time technicians to cover these occasional, labor-intensive time points. Therefore, the core is integral and critical to the goals of each of the projects and required for consistency between projects so that results between projects can be directly compared. Core B will support the RMRCE Integrated Research Foci on Immunomodulation, Adjuvants and Vaccines (IRF 1) as well as Bacterial Therapeutics (IRF 2), and its resources will be utilized by RPs 1.1, 1.2, 1.3, and 2.4.

Public Health Relevance

The RMRCE Coxiella projects are designed to collectively develop non-specific adjuvants and specific vaccines to Q fever. The Core will supply a consistent and well characterized source of C. burnetii so that results of experiments by any one of the projects can be compared to results from the other projects. Thus, the core is central to the development of immunotherapies against Q fever.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-08
Application #
8375726
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
8
Fiscal Year
2012
Total Cost
$33,055
Indirect Cost
$6,954
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Lehman, Stephanie S; Mladinich, Katherine M; Boonyakanog, Angkana et al. (2016) Versatile nourseothricin and streptomycin/spectinomycin resistance gene cassettes and their use in chromosome integration vectors. J Microbiol Methods 129:8-13
Knudson, Susan E; Cummings, Jason E; Bommineni, Gopal R et al. (2016) Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis. Tuberculosis (Edinb) 101:8-14
Charley, Phillida A; Wilusz, Jeffrey (2016) Standing your ground to exoribonucleases: Function of Flavivirus long non-coding RNAs. Virus Res 212:70-7
Phillips, Aaron T; Rico, Amber B; Stauft, Charles B et al. (2016) Entry Sites of Venezuelan and Western Equine Encephalitis Viruses in the Mouse Central Nervous System following Peripheral Infection. J Virol 90:5785-96
Westover, Jonna B; Sefing, Eric J; Bailey, Kevin W et al. (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62-8
Shankar, Sundaresh; Whitby, Landon R; Casquilho-Gray, Hedi E et al. (2016) Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein. J Virol 90:6799-807
York, Joanne; Nunberg, Jack H (2016) Myristoylation of the Arenavirus Envelope Glycoprotein Stable Signal Peptide Is Critical for Membrane Fusion but Dispensable for Virion Morphogenesis. J Virol 90:8341-50
Rhodes, Katherine A; Schweizer, Herbert P (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82-90
Voge, Natalia V; Perera, Rushika; Mahapatra, Sebabrata et al. (2016) Metabolomics-Based Discovery of Small Molecule Biomarkers in Serum Associated with Dengue Virus Infections and Disease Outcomes. PLoS Negl Trop Dis 10:e0004449
Rico, Amber B; Phillips, Aaron T; Schountz, Tony et al. (2016) Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses. Virology 499:30-39

Showing the most recent 10 out of 244 publications